Context: Erectile function is important for life satisfaction and often impaired in men with obstructive sleep apnea (OSA). Uncontrolled studies show that treating OSA with continuous positive airway pressure (CPAP) improves erectile function. Phosphodiesterase type 5 inhibitors (e.g., vardenafil) are the first-line therapy for erectile dysfunction (ED), but may worsen OSA.
T he prevalence of erectile dysfunction (ED), the inability to attain or maintain penile erection sufficient for penetration, is present in ;50% to 60% of men aged 40 to 70 years (1) and has been identified as an early warning sign for developing cardiovascular disease (2) . Obstructive sleep apnea (OSA) is characterized by sleep fragmentation and intermittent blood oxygen desaturation from repetitive obstruction of the upper airway during sleep. An estimated 24% of men aged 30 to 60 years are affected by at least mild OSA, as defined by an apneahypopnea index (AHI) $5 (3). Furthermore, moderate to severe OSA is associated with an increased risk of cardiovascular disease and mortality (4) and sometimes occurs in the presence of hypogonadism, for which testosterone therapy may be considered (5, 6) .
ED and OSA often coexist, with approximately half of men with one condition having the other (7) (8) (9) . This association remains even after accounting for common risk factors such as obesity and increasing age and comorbidities such as diabetes, hypertension, depression, and cardiovascular disease (8) , although one recent study in men aged 67 years or older did not concur (10) . Possible mechanisms include a reduction of testosterone, interruption to sleep-related erections, or endothelial dysfunction (6, 9, (11) (12) (13) . Previous research on the effect of continuous positive airway pressure (CPAP), the standard therapy for OSA, on ED are limited to studies that have been uncontrolled, inadequately controlled, or included study participants who did not have ED (14) (15) (16) (17) (18) (19) . A randomized sham-controlled study has not been previously reported and is needed because ED is a patient-reported outcome that is susceptible to the placebo effect. Furthermore, erectile and sexual function are greatly valued by many men, so compliance might be improved if CPAP could be unequivocally shown to improve ED. Although CPAP may increase testosterone in hypogonadal men with OSA, testosterone replacement therapy is usually still required, and in this circumstance, adherent CPAP to prevent worsening OSA is required (5, (20) (21) (22) .
The first-line treatment of ED is phosphodiesterase type 5 (PDE-5) inhibitor, used on demand. However, the safety of PDE-5 inhibitors has been questioned in patients with OSA, with a small randomized controlled study in severe OSA reporting an increase in OSA severity with an on-demand dose of 50 mg sildenafil (23) . Therefore, a lower daily dose could be an alternative treatment regimen in these patients, which requires further investigation. Vardenafil 10 mg daily has been successfully used to treat ED and is equivalent to on-demand therapy (24) . In this randomized sham-controlled study, we assessed the effect of CPAP and a low daily dose of vardenafil given at night on sexual function in men with both OSA and ED, while also measuring sleep-related erections, endothelial function, arterial stiffness, hormone levels, quality of life, and sleep-disordered breathing, to investigate possible mechanisms underlying the two conditions. The nighttime dosing was to maximize effects on sleep, breathing, and nocturnal penile tumescence. We also evaluated the efficacy of CPAP and vardenafil on subjects who were adherent to each therapy because nonadherent therapy would not be expected to improve outcomes or unveil mechanisms.
Methods

Study design
The study was conducted at the Woolcock Institute of Medical Research (Sydney, New South Wales, Australia) and Monash Medical Centre Sleep Unit (Clayton, Victoria, Australia). This was a randomized controlled trial with a two-by-two factorial design allowing separate evaluation of the effects of CPAP vs sham CPAP and the PDE-5 inhibitor drug vardenafil vs placebo on erectile function in men with both OSA and ED. Men aged 18 to 65 years were included in the study if they had moderate to severe OSA [AHI $20 events/h and oxygen desaturation index $15 events/h (oxygen desaturation of $3%)], were CPAP naive, and had ED determined by a score ,26 in the erectile function domain of the International Index of Erectile Function (IIEF) questionnaire. Full inclusion criteria are listed in the Supplemental Methods. We also prespecified definitions of adherence to CPAP as being usage $4 hours per night on average and, for vardenafil, $80% tablets taken over the duration of the 12-week study period.
This study protocol was approved by the Human Research Ethics Committee, Concord Repatriation General Hospital (Concord, New South Wales, Australia) and Monash Health Human Research Ethics Committee (Clayton, Victoria, Australia). All participants provided written informed consent. This was an investigator-initiated study, supported by the National Health and Medical Research Council, Australia (project grant 632833) and Bayer Pharma AG. Philips Respironics donated CPAP and sham CPAP equipment and Bayer Pharma AG donated vardenafil and matching placebo. Philips Respironics and Bayer Pharma AG were not involved in study conduct, data analyses, or manuscript preparation. All of the authors assure the accuracy and completeness of the data. The study is registered with the Australia New Zealand Clinical Trials Registry, (ACTRN12610000144011).
Randomization, allocation concealment, and blinding
Participants were randomized in a two-by-two factorial design to CPAP or sham, and vardenafil or placebo. Men were allocated on a 1:1:1:1 basis to CPAP + vardenafil, CPAP + placebo, sham + vardenafil, and sham + placebo. The randomization sequence was generated by computer program (the blockrand function in R) using random permuted blocks. Separate sequences were generated to achieve stratification by the two study centers. Printed cards allocating CPAP or sham were labeled sequentially by randomization number and placed in opaque, sealed envelopes by an individual independent of the study staff or investigators. CPAP machine preparation, download, and troubleshooting was performed by personnel separate to the study investigators and not involved in participant assessments. A trial pharmacist who was not otherwise involved with the study prepared the study medication (vardenafil or placebo) in identically appearing bottles labeled by randomization number using the generated allocation list. The participants and study investigators were blinded to treatment allocation (and adherence) for the duration of the trial.
OSA intervention
For participants allocated to receive real CPAP, the individual pressure requirement was determined via a minimum 3-night home autotitration using a Remstar Pro CPAP machine (Philips Respironics, Pittsburgh, PA). Participants then used the device at these settings at home for the remainder of the 12 weeks. Those participants allocated to receive sham CPAP completed the same procedure using a manufactured sham version of the Remstar Pro (Philips Respironics). Sham CPAP comprised an adapted machine and mask that ensured that the patient received subtherapeutic (,0.5 cm H 2 O) therapy but experienced all other facets of CPAP use. Compliance data were recorded by an internal clock within all real and sham CPAP machines and downloaded after the home titration and at each visit.
ED intervention
Participants received either 10 mg vardenafil hydrochloride trihydrate (Levitra; GlaxoSmithKline, Warren, NJ) or placebo (Bayer Schering, Berlin, Germany) for 12 weeks. Medication sufficient for a 4-week period was dispensed at baseline, week 4, and week 8 with any remaining tablets returned at the next visit. Participants were instructed to take one tablet daily 1 hour before attempting to fall asleep, regardless of their intention to attempt sexual activity. Returned tablets were counted to assess adherence with treatment.
End points
The prespecified primary end point was erectile function as measured by the IIEF questionnaire (25) , which is a U.S. Food and Drug Administration-recognized patient-reported outcome. This was measured at 4, 8, and 12 weeks, with the measurement at 12 weeks being of primary interest. Objective secondary end points were sleep-related erection frequency using nocturnal penile tumescence monitoring (Rigiscan; Timm Medical Technologies, Chesterbrook, PA); endothelial function by brachial artery flow-mediated dilatation; peripheral arterial tonometry (EndoPAT; Itamar Medical Ltd, Caesarea, Israel); and arterial stiffness using peripheral arterial tonometry and pulse wave analysis (Sphymo-Cor; AtCor Medical, Sydney, New South Wales, Australia) (26) . Other patient-reported secondary end points were measurements of sexual function and relationship quality using nonerectile domains of the IIEF and European Male Aging Study-Sexual Function Questionnaire (27) and Self-Esteem and Relationship Satisfaction (SERS) (28) questionnaires. General quality of life was assessed using Short-Form 36, mood using the Depression Anxiety Stress Scale (29), sleep-related quality of life by the Functional Outcome of Sleep Questionnaire (21) , and sleepiness using the Epworth Sleepiness Scale (30) . Treatment satisfaction was evaluated by the Erectile Dysfunction Index Treatment Satisfaction questionnaire (31) . Luteinizing hormone, follicle-stimulating hormone, and total testosterone were measured as previously described (21) .
Statistical analysis
A sample size of 50 was estimated to yield 80% power to detect either a 5.6-point improvement between interventions in the total IIEF score or a 2.3-point increase in the erectile function subscale of the IIEF with a set at 0.05, assuming standard deviations (SDs) of 6.8 and 2.8, respectively (15, 32) . To allow for noncompletion, 61 subjects were recruited.
Statistical analysis was performed using SAS statistical package version 9.3 (SAS Institute, Cary, NC). The randomization code was broken only after all data were collected, then cleaned, and the database locked. Student t tests established any differences in groups at baseline. Data were analyzed using intention-to-treat principles and following established guidelines on factorial randomized controlled trials (33, 34) . Briefly, mixed models were used with a repeated statement to account for outcomes with multiple observations within each subject under a compound symmetry covariance structure. Initially, the presence of noteworthy CPAP*drug*time and CPAP*drug interactions were excluded (Supplemental Table 1 ). Hence, subsequent analyses of the two interventions were performed separately with each model including treatment (either CPAP/ sham or vardenafil/placebo), time (weeks 4, 8, and 12), and their interaction, with the difference between interventions at week 12 being of interest. General linear models were used to determine differences between treatments for outcome variables with a single observation. The baseline value of the outcome was included as a covariate in all models. Perprotocol analysis was then undertaken in the same manner to examine the influence of CPAP and vardenafil adherence on the effect of treatment. Preset criteria for adherent CPAP use (usage of at least 4 hours per night) and vardenafil use (at least 80% usage of medication) were used to define the per-protocol populations (35) . Post hoc analyses of participants with severe ED (IIEF-ED score of 5 to 11) at baseline and those who improved four or more points on the IIEF-ED were also conducted. Data are presented as mean 6 SD or between-group differences with 95% confidence intervals (CIs).
Results
Study participants
Between 1 May 2010 and 15 March 2013, 84 men were screened, and 61 men were randomized into the study. The flow of participants is shown in Supplemental Fig. 1 . Six men withdrew from the study after randomization; therefore, 55 men completed both the CPAP and vardenafil studies. Baseline characteristics were similar between the treatment groups for both the intention-to-treat and per-protocol populations (Table 1) .
There was no difference in average CPAP use between the CPAP group (3.7 6 2.5 hours/night) and the sham CPAP group (2.6 6 2.2 hours/night; P = 0.09). The perprotocol population in the OSA intervention included 20 men (12 and 8 in the CPAP and sham CPAP groups, respectively) who met the prespecified adherence criteria. Treatment usage in the per-protocol population was 6.2 6 0.9 hours/night for the CPAP group and 5.1 6 1.2 hours/night for the sham CPAP group (P = 0.15). Similarly, medication adherence was not different between vardenafil (84.0%) and placebo (84.5%) (P = 0.92). The per-protocol population in the ED intervention was defined as taking $80% prescribed tablets, which was achieved by 42 men (21 in the vardenafil group and 21 in the placebo group; P = 0.99).
Compared with sham CPAP, CPAP effectively reduced the severity of OSA as measured by AHI in the intentionto-treat population [between-group difference of change from baseline: 241.6 events/h (95% CI 254.7 to 228.4); P , 0.001] and per-protocol population [239.9 events/h (265.9 to 214.0); P = 0.0006]. There were no changes in sleep duration or proportion of rapid eye movement (REM) sleep (all P . 0.28). Compared with placebo, vardenafil had no effect on AHI in either the intention-totreat [between-group difference: 2.82 events/h (211.3 to 17.0); P = 0.69] or per-protocol population analysis [5.5 events/h (210.6 to 21.6); P = 0.49], nor were there any effects on any other sleep variable (data not shown). Data are means 6 SD unless otherwise indicated. There were no significant differences for any of the baseline characteristics (P . 0.05). Adherent CPAP group included participants who met prespecified adherence criteria of $4 h use per night.
Abbreviation: SpO 2 , arterial oxygen saturation. a The body mass index is the weight in kilograms divided by the square of the height in meters.
b The AHI is the number of apnea and hypopnea episodes per hours of sleep time.
c Scores on the Epworth sleepiness scale range from 0 to 24, with higher scores indicating more daytime sleepiness.
d Hormone values are from a single morning sample.
e Free testosterone was calculated by the Vermeulen equation.
f Overall scores on the IIEF range from 6 to 75, with lower levels indicating lower sexual function, which includes sexual desire, erectile function and orgasmic function. g Scores on the Erectile Function domain range from 6 to 30, with lower scores indicating less erectile function and ED defined as being a score ,26. h Severe ED defined as an IIEF-ED score 5 to 11 inclusive.
Patient-reported erectile function (IIEF)
Compared with sham, CPAP did not improve erectile function as measured by the IIEF erectile function domain and the overall score, but did improve overall satisfaction in the intention-to-treat population (Table 2 ). There was no change in any other subjective measure of sexual function (Table 2 and Supplemental Table 2 ). In men who met the prespecified adherence criteria, adherent CPAP use improved the IIEF components of erectile function, sexual desire, as well as the overall score compared with sham CPAP (Table 2) . Additional improvements were seen in self-esteem and sexual relationship satisfaction from the SERS and overall sexual function and distress due to sexual function from the European Male Aging Study-Sexual Function Questionnaire (Supplemental Table 2 ). Compared with placebo, vardenafil did not result in a statistically noteworthy improvement in either the erectile function domain or overall score of the IIEF (Table 3) . Vardenafil reduced distress due to sexual functioning and improved the overall score in the SERS questionnaire. Adherence to vardenafil additionally improved confidence and self-esteem in relation to sexual function (Supplemental Table 3 ).
Additionally, the linear effect of severity was assessed in the mixed model by the inclusion of a treatment*baseline severity interaction term. We also found no differences in the number of people who reported a clinically important improvement (defined as an increase in $4.0 points) between CPAP and sham (14 vs 9; Fisher exact test, P = 0.41) or vardenafil and placebo (13 vs 10; P = 0.59).
Nocturnal penile tumescence
Nocturnal penile tumescence monitoring was successfully recorded on 28 men who agreed to undertake this procedure (CPAP: n = 15; sham CPAP: n = 13; vardenafil: n = 15; placebo, n = 13). CPAP increased the number of sleep-related erections compared with sham CPAP [between-group difference: 1.7 (95% CI 0.5 to 2.9); P = 0.007] in this group, but did not change any parameters of tumescence or rigidity (Table 4) . Vardenafil did not significantly increase the number of sleep-related erections compared with placebo or any other measures of tumescence and rigidity (Table 4) .
Reproductive hormones
Baseline testosterone levels spanned the lower part of the normal young adult reference range (10.2 6 3.7 nmol/L). Neither CPAP nor vardenafil increased testosterone, luteinizing hormone, follicle-stimulating hormone, prolactin, or sex hormone-binding globulin in either the intention-to-treat (all P . 0.22) or per-protocol populations (all P . 0.06). Vascular function CPAP significantly improved arterial stiffness measured using pulse wave analysis and peripheral arterial tonometry (both P , 0.05). In contrast, there was no change in either macrovascular or microvascular endothelial function, as measured by flow-mediated dilatation and peripheral arterial tonometry, respectively (Table 5 ). In the per-protocol population, similar results were observed in both the peripheral arterial tonometry measures; however, the effects on flow-mediated dilatation and pulse wave analysis were not reported due to insufficient numbers (Table 5) .
Vardenafil did not affect any measure of vascular function in either the intention-to-treat or per-protocol analyses ( Table 6 ).
Quality of life
In the intention-to-treat population, CPAP did not alter the overall score for Short- 
Discussion
This randomized sham-controlled study investigated the effect of CPAP and vardenafil on erectile function in men with both OSA and ED. Using a factorial two-by-two, randomized, controlled trial design, this study shows that CPAP improves sexual satisfaction, increases the number of sleep-related erections, and reduces arterial stiffness, but not patient-reported erectile function. However, erectile function improved in men who adhered to treatment, as did overall sexual function, sexual desire, treatment satisfaction, self-esteem and relationships, and sleepiness. Continuous lower-dose vardenafil did not alter erectile function and did not consistently improve sleep-related erectile tumescence and rigidity, but did increase treatment satisfaction as well as self-esteem and confidence in those adherent to medication. Vardenafil did not worsen sleep-disordered breathing. In our study, overall, CPAP did not improve erectile function as measured by the gold standard patientreported outcome, IIEF; however, there were improvements with objectively measured erectile function during sleep and subjective satisfaction with sexual function. Previous studies have shown an improvement in IIEF; however, design limitations include a lack of control group or adequate sham control (14, 15, 17, 18) , which may have overestimated the treatment effect. Given the subjective nature of the outcome, sham controls are essential. Nocturnal erections have been proposed to have a role in maintaining erectile function (36) (37) (38) , and hence improvements may precede any daytime effects on the latter. Our finding that the number of erections increased for the participants who undertook this monitoring may support this. The duration of REM sleep, the stage of sleep when nocturnal erections occur, did not change after treatment, which suggests REM duration is not a determining factor. Testosterone and gonadotropins also did not change, possibly due to no effects on REM.
Vardenafil increased the main outcome of IIEF-EF score by four points; however, this was not a statistically meaningful change. The change observed in this study is comparable to a previous randomized controlled trial using a once-daily regimen with the same drug and dose in comparison with on-demand dosing (24) . In this study, on-demand and daily vardenafil dosing had comparable effects on IIEF-EF. A meta-analysis of vardenafil studies using on-demand doses between 5 and 20 mg reported increases in the IIEF-EF domain by a mean of 6.2 points (39) . Other studies support the efficacy of continuous rather than on-demand dosing of vardenafil (40) . Our own data showed nonsignificant increases in nocturnal tumescence and rigidity with vardenafil. Therefore, the lack of change observed in our current study suggests that men with OSA may be partly resistant to low-dose continuous PDE-5 inhibitor use because none of the studies using a once-daily dose formally defined or reported whether patients had or were treated for OSA. As the safety of PDE-5 inhibitor use in OSA has been called into question (41, 42) , it is important to understand whether a lower daily dose is both efficacious and safe in this patient population. Parameters of sleep-disordered breathing were not worsened in this study. Furthermore, the increase in the IIEF-EF domain would be considered clinically relevant, albeit on the lower end of the spectrum (43) . Nevertheless, our study supports the safety but cannot confirm the efficacy of a lower daily dose of vardenafil in patients with both OSA and ED. In clinical practice, the dose of a PDE-5 inhibitor would be maximized, if the clinical response were unsatisfactory. We did not show a change in endothelial function measured by flow-mediated dilatation or peripheral arterial tonometry with either vardenafil or CPAP. The lack of an effect with CPAP thus does not support the proposed mechanistic link involving endothelial dysfunction between OSA and ED, which has been postulated by us and others (9) . Positive effects of CPAP have been reported in randomized trials in populations not selected for ED; however, we might have expected enhanced effects from our population of patients with ED (9). Potentially, the smaller numbers for which these outcomes were available may have reduced statistical power. Considering other potential mechanisms for the improvement in ED, we found CPAP decreased arterial stiffness but did not increase serum testosterone. Improvements in arterial stiffness with CPAP were seen using two independent measurements in both the intention-to-treat and per-protocol group. The reduction in the augmentation index we found of 6.4% is similar to a previous randomized sham-controlled study that reported a decrease of 5.4% in men with OSA, but not assessed for ED (44) .
A study limitation was that only ;40% of participants met the prespecified adherence criteria (i.e., $4 h/night on average) to allow inclusion in the CPAP per-protocol analysis. Suboptimal adherence to CPAP may have limited the effect seen with treatment; however, this adherence rate is comparable to other sham-controlled studies and would be representative of real-world practice in a general OSA population (45) . For this reason, a per-protocol analysis to unveil mechanisms was an important part of the statistical analysis plan. In fact, overall satisfaction and improved arterial stiffness were numerically greater in magnitude in those who were adherent to CPAP compared with the group unselected for adherence. These data provide evidence that 4 hours of CPAP use is sufficient to improve erectile function in men with OSA, also presenting with ED, supporting similar data for improving sleepiness and vascular function in men with OSA. In contrast, 75% of patients were adherent with medication, which most likely explains the lack of difference between the intention-totreat and per-protocol analyses for the vardenafil study. Furthermore, we report unadjusted P values for our secondary end points, and therefore, the effect of multiple comparisons should be considered when interpreting these results. We also did not investigate any synergistic effects of CPAP and vardenafil treatment because the recruitment target to be adequately powered to detect an interaction between treatments would have made the trial impractical.
A future trial will be required to address this issue. Despite this, we have undertaken this study to understand the individual effects of vardenafil and CPAP in men with OSA and ED. This study demonstrates that CPAP improves sexual satisfaction, increases the number of sleep-related erections, and reduces arterial stiffness. Additionally, adherent CPAP use was associated with further improvements in erectile and sexual function, as well as quality of life. These data may convince some men who highly value erectile function to adhere to CPAP therapy. Using vardenafil for treatment of ED in this population does not worsen sleepdisordered breathing and may result in clinically important improvements in sexual function, but remains costly and does not seem to have the broad range of benefits that we unveiled for CPAP use. Alternative interventions addressing both OSA and ED, including weight loss, will need to be explored.
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